ATLANTA, GA – – (Newsfile Corp. – December 6, 2021) – – Holzer & Holzer, LLC is investigating whether Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) complied with federal securities laws. On December 6, 2021, the U.S. Food and Drug Administration (“FDA”) released briefing documents ahead of an Advisory Committee meeting regarding CARDINAL, a phase 3 study conducted in support of the New Drug Application for bardoxolone. In the briefing documents, the FDA indicated that the “loss of statistical significance based on a change in a single factor in the analytic model raises concerns regarding the robustness of the study’s findings.” On this news the Company’s stock dropped. If you purchased Reata stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

Provide Your Information To Take Action

  • Date PurchasedNumber of Shares AcquiredAcquisition Price Per Share 
  • Date SoldNumber of Shares SoldSelling Price Per Share 
  • Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt